Scientists are making a vaccine expected to be the first immunization against invasive fungal infections. Moreover, although it has only been tested on animals to date, the research can tackle the threat of drug-resistant fungi through this broad-spectrum vaccine.
An experimental vaccine was made recently in a study to protect against Aspergillus, Candida, and Pneumocystis, which are the three most common fungi that cause more than 80% of fatal infections.
Based on the experiments conducted by the University of Georgia, rodents and non-human primates had better chances of survival after the vaccine. Moreover, the shot effectively developed protective antibodies against all three fungal pathogens.
Karen Norris, the lead investigator said,
Because it targets three different pathogens, the vaccine has the potential to be groundbreaking regarding invasive fungal infections,
Norris further added,
Plans are underway to develop the vaccine for a Phase I (human) safety trial
Currently, no vaccines are approved for fungal infections. Furthermore, although a fungi pandemic is least expected, the threat of drug resistance is growing.
More experimental treatments are being worked on. However, the world is not prepared for drug-resistant fungi infections. Moreover, the first line of defence against human infections is broad-spectrum anti-fungal medications. Unfortunately, the growing number of superbug fungi is causing resistance to these drugs because of anti-fungal overuse. Mostly in industrial areas.
Tricky Fungal Infections
In 2021, scientists reported the spread of tricky fungal infections among COVID-19 patients during the peak pandemic. Furthermore, people with a weak immune system are at a higher risk, especially if they are exposed to hospital settings with an infection spread. A vaccine will be a lifesaver for such people.
However, since it is still in the early stages, it will take time before people can benefit from this shot.
Norris said,
This is an area that has been underdeveloped on the research front for a long time,
These are very large populations of people who are at risk of invasive fungal infections, and although there have been considerable efforts to develop vaccines, none are yet approved. We believe this is a very strong vaccine candidate,
